{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:02:36Z","timestamp":1794499356675,"version":"4.9.1"},"reference-count":46,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2022,1,4]]},"abstract":"<jats:p>Background: Studies 4658-201\/202 (201\/202) evaluated treatment effects of eteplirsen over 4 years in patients with Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations. Chart review Study 4658-405 (405) further followed these patients while receiving eteplirsen during usual clinical care. Objective: To compare long-term clinical outcomes of eteplirsen-treated patients from Studies 201\/202\/405 with those of external controls. Methods: Median total follow-up time was approximately 6 years of eteplirsen treatment. Outcomes included loss of ambulation (LOA) and percent-predicted forced vital capacity (FVC%p). Time to LOA was compared between eteplirsen-treated patients and standard of care (SOC) external controls and was measured from eteplirsen initiation in 201\/202 or, in the SOC group, from the first study visit. Comparisons were conducted using univariate Kaplan-Meier analyses and log-rank tests, and multivariate Cox proportional hazards models with regression adjustment for baseline characteristics. Annual change in FVC%p was compared between eteplirsen-treated patients and natural history study patients using linear mixed models with repeated measures. Results: Data were included from all 12 patients in Studies 201\/202 and the 10 patients with available data from 405. Median age at LOA was 15.16 years. Eteplirsen-treated patients experienced a statistically significant longer median time to LOA by 2.09 years (5.09 vs. 3.00 years, p\u200a&lt;\u200a0.01) and significantly attenuated rates of pulmonary decline vs. natural history patients (FVC%p change: \u20133.3 vs. \u20136.0 percentage points annually, p\u200a&lt;\u200a0.0001). Conclusions: Study 405 highlights the functional benefits of eteplirsen on ambulatory and pulmonary function outcomes up to 7 years of follow-up in comparison to external controls.<\/jats:p>","DOI":"10.3233\/jnd-210665","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T12:44:12Z","timestamp":1629463452000},"page":"39-52","source":"Crossref","is-referenced-by-count":50,"title":["A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment"],"prefix":"10.1177","volume":"9","author":[{"given":"Olga","family":"Mitelman","sequence":"first","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the investigators from the LNMRC Natural History study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the investigators from the CINRG Duchenne National History Study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the investigators from The DMD Italian Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda Z.","family":"Abdel-Hamid","sequence":"additional","affiliation":[{"name":"UPMC Children\u2019s Hospital of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Connolly","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, The Ohio State University College of Medicine, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Heydemann","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Proud","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of The King\u2019s Daughters, Norfolk, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[{"name":"University of California Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Dugar","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Santra","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[{"name":"University of California Davis Health System, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Catholic University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, The Ohio State University College of Medicine, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"6","key":"10.3233\/JND-210665_ref1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"3","key":"10.3233\/JND-210665_ref2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"issue":"1","key":"10.3233\/JND-210665_ref3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases\u2013a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.3233\/JND-210665_ref4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of Duchenne and Becker muscular dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"issue":"1","key":"10.3233\/JND-210665_ref5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.3233\/JND-210665_ref6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.3233\/JND-210665_ref7","doi-asserted-by":"crossref","unstructured":"Emery AEH , Muntoni F , Quinlivan R . Duchenne muscular dystrophy. 4th ed. Oxford: Oxford University Press; 2015. ix, pp. 308.","DOI":"10.1093\/med\/9780199681488.001.0001"},{"issue":"3","key":"10.3233\/JND-210665_ref8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.3233\/JND-210665_ref9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","article-title":"Functional changes in Duchenne muscular dystrophy: A 12-month longitudinal cohort study","volume":"77","author":"Mazzone","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JND-210665_ref10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","article-title":"The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle Nerve"},{"issue":"24","key":"10.3233\/JND-210665_ref12","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/JND-210665_ref13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/00207454.2020.1740218","article-title":"Common therapeutic advances for Duchenne muscular dystrophy (DMD)","volume":"131","author":"Salmaninejad","year":"2021","journal-title":"Int J Neurosci"},{"issue":"5","key":"10.3233\/JND-210665_ref15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mus.26161","article-title":"Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history","volume":"58","author":"Arora","year":"2018","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.3233\/JND-210665_ref16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","article-title":"Reliability of the North Star Ambulatory Assessment in a multicentric setting","volume":"19","author":"Mazzone","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.3233\/JND-210665_ref17","doi-asserted-by":"crossref","first-page":"e52512","DOI":"10.1371\/journal.pone.0052512","article-title":"24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy","volume":"8","author":"Mazzone","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.3233\/JND-210665_ref18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): An exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.3233\/JND-210665_ref19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.3233\/JND-210665_ref20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"THE 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.3233\/JND-210665_ref21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nmd.2013.05.006","article-title":"Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids","volume":"23","author":"Goemans","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.3233\/JND-210665_ref22","doi-asserted-by":"crossref","first-page":"e83400","DOI":"10.1371\/journal.pone.0083400","article-title":"6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes","volume":"9","author":"Pane","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.3233\/JND-210665_ref23","doi-asserted-by":"crossref","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"Pane","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.3233\/JND-210665_ref24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.3233\/JND-210665_ref25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"issue":"10119","key":"10.3233\/JND-210665_ref26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.3233\/JND-210665_ref27","doi-asserted-by":"crossref","first-page":"e0218683","DOI":"10.1371\/journal.pone.0218683","article-title":"Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53","volume":"14","author":"Brogna","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JND-210665_ref28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy","volume":"28","author":"Goemans","year":"2018","journal-title":"Neuromuscular Disorders"},{"issue":"Preprint","key":"10.3233\/JND-210665_ref29","first-page":"1","article-title":"Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial","author":"McDonald","year":"2021","journal-title":"Journal of Neuromuscular Diseases. (Preprint)"},{"key":"10.3233\/JND-210665_ref30","doi-asserted-by":"crossref","unstructured":"ATS statement: Guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine. 2002;166(1):111\u20137.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"issue":"4","key":"10.3233\/JND-210665_ref31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","article-title":"DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study","volume":"87","author":"Bello","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JND-210665_ref32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U. S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.3233\/JND-210665_ref33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3233\/JND-180351","article-title":"Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy","volume":"6","author":"Khan","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.3233\/JND-210665_ref34","unstructured":"Polgar G , Promadhat V . Pulmonary function testing in children: Techniques and standards: Saunders Limited.; 1971."},{"issue":"10","key":"10.3233\/JND-210665_ref35","doi-asserted-by":"crossref","first-page":"e1381","DOI":"10.1212\/WNL.0000000000010170","article-title":"Suitability of external controls for drug evaluation in Duchenne muscular dystrophy","volume":"95","author":"Goemans","year":"2020","journal-title":"Neurology"},{"issue":"9","key":"10.3233\/JND-210665_ref36","doi-asserted-by":"crossref","first-page":"e0161955","DOI":"10.1371\/journal.pone.0161955","article-title":"Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an open-label extension study","volume":"11","author":"Goemans","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JND-210665_ref37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"2","key":"10.3233\/JND-210665_ref38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpn.2011.07.001","article-title":"Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trials","volume":"16","author":"Humbertclaude","year":"2012","journal-title":"European Journal of Paediatric Neurology"},{"issue":"2","key":"10.3233\/JND-210665_ref39","first-page":"117","article-title":"Survival in Duchenne muscular dystrophy","volume":"31","author":"Rall","year":"2012","journal-title":"Acta Myol"},{"issue":"3","key":"10.3233\/JND-210665_ref40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpn.2006.12.002","article-title":"Predictive factors for the development of scoliosis in Duchenne muscular dystrophy","volume":"11","author":"Kinali","year":"2007","journal-title":"European Journal of Paediatric Neurology"},{"issue":"4","key":"10.3233\/JND-210665_ref41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cupe.2005.04.001","article-title":"The multidisciplinary management of Duchenne muscular dystrophy","volume":"15","author":"Bushby","year":"2005","journal-title":"Current Paediatrics"},{"issue":"4","key":"10.3233\/JND-210665_ref42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"The Lancet Neurology"},{"issue":"10119","key":"10.3233\/JND-210665_ref43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"The Lancet"},{"issue":"15 Supplement","key":"10.3233\/JND-210665_ref44","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1212\/WNL.94.15_supplement.1398","article-title":"Delays in progression of Duchenne muscular dystrophy with eteplirsen treatment: attenuation of pulmonary function decline and projected freedom from continuous ventilation","volume":"94","author":"Iff","year":"2020","journal-title":"Neurology"},{"issue":"9","key":"10.3233\/JND-210665_ref45","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/humu.23561","article-title":"DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype","volume":"39","author":"Wang","year":"2018","journal-title":"Hum Mutat"},{"issue":"11","key":"10.3233\/JND-210665_ref46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nmd.2018.07.004","article-title":"Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids","volume":"28","author":"McDonald","year":"2018","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.3233\/JND-210665_ref47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle & Nerve"},{"key":"10.3233\/JND-210665_ref48","first-page":"S108","article-title":"P","volume":"29","author":"Goemans","year":"2019","journal-title":"202A composite prognostic score for time to loss of walking ability in Duchenne muscular dystrophy (DMD). Neuromus Dis"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:53Z","timestamp":1777506593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":46,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210665","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]}}}